Navigation Links
MDS Nordion Provides Update on AECL's Medical Isotope Supply Disruption
Date:5/19/2009

OTTAWA, May 19 /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, has received information from its primary supplier, Atomic Energy of Canada Limited (AECL), regarding an interruption in the supply of medical isotopes, primarily molybdenum-99 (Mo-99) used in the manufacturing of technetium-99m generators.

AECL has advised MDS Nordion that they anticipate the National Research Universal reactor (NRU) will remain out of service for more than one month. According to a press release issued by AECL on May 18, 2009, the shutdown is a result of a heavy water leak that has been identified at the base of the reactor vessel. AECL has indicated that repair options are currently under consideration.

MDS Nordion expects the impact of this shutdown to begin to be felt this week. The NRU produces approximately 30%-40% of the world's medical isotopes and approximately 50% of those used in North America, and is one of only four reactors in the world with the capacity to produce significant commercial quantities. While MDS Nordion is working closely with its supply network to source additional isotopes, based on AECL's information and global supply capability, the Company expects that the medical community and their patients will experience a significant shortage of isotopes worldwide.

MDS Nordion recognizes the important role medical isotopes play in the diagnosis and treatment of life-threatening conditions such as heart disease and cancer. The Company continues to work to secure a reliable, long-term supply of medical isotopes. In 1996, MDS Nordion contracted for AECL to complete and commission the MAPLE reactors, which were meant to replace the NRU. This project was unilaterally discontinued in May 2008 by the federal government and AECL. MDS Inc.'s investment in the MAPLE project was approximately US$350 million. MDS believes that the completion of the MAPLE project is the best alternative to provide long-term global isotope supply.

In addition to MAPLE, MDS Nordion is examining longer-term supply alternatives. One such program is MDS Nordion's recently announced collaboration with TRIUMF, Canada's national laboratory for particle and nuclear physics, to study the feasibility of producing a viable and reliable supply of photo fission-based Mo-99.

Based on this latest update from AECL, MDS Inc. expects the financial impact of this extended interruption to reduce MDS Nordion's adjusted EBITDA by approximately US$4 million per month.

More Information

Additional background pertaining to today's announcement can be found on MDS Inc.'s Website at http://www.mdsinc.com/for_media/electronic_media_kit.asp

About MDS Nordion

MDS Nordion, a business unit of MDS Inc., is a global leader in providing medical isotopes for molecular and diagnostic imaging, radiotherapeutics and sterilization technologies for medical products that benefit the lives of millions of people in more than 50 countries around the world. MDS Nordion products and services are used on a daily basis by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Find out more at www.mdsnordion.com

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,000 highly skilled people in 29 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

Forward-Looking Statements

This document contains forward-looking statements. Some forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "indicates", "targeted" or similar expressions. The statements are not a guarantee of future impact or performance and are inherently subject to risks and uncertainties. The actual impact to the Company of the maintenance shutdown could differ materially from that currently anticipated due to a number of factors, including, the actual timing of a return to full production and other risk factors identified in other documents filed by the Company with Canadian and U.S. securities regulatory authorities from time to time.


'/>"/>
SOURCE MDS Nordion
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MDS Nordion Launches Improved TheraSphere(R) Administration System for Physicians
2. Dr. Peter Covitz Joins MDS Nordion as Senior Vice-President Innovation
3. MDS Nordion Provides Update to Medical Isotope Customers
4. MDS Nordion Divests Non Strategic Product Lines
5. MDS Nordion signs 17-year contract with Rosenergoatom
6. Taking a Bite Out of Rabies: Merial Provides Rabies Awareness and Prevention Training to Noahs Wish Pet Disaster Relief Organization
7. Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes
8. National Autism Association Provides Funds to Law Enforcement Agencies in Staunton, Virginia and Summit County, Utah for Project Lifesaver Equipment
9. All Allied Health Schools Provides Public Health Students with Career and Education Resources
10. Mayo Clinic researchers say agent provides treatment option for women with hot flashes
11. MTF, Largest Tissue Bank, Provides Skin for Victims of Santa Barbara Wildfires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: